Select region:

Clinical trials located in

La Tronche

La Tronche city is located in France. Currently, 20 clinical trials are being conducted in this city.

La Tronche is a French city located in the Auvergne-Rhône-Alpes region, adjacent to Grenoble. Known for its rich history and cultural heritage, it houses the Museum Hebert, set in a 19th-century villa showcasing French art. The city is also home to the renowned Grenoble-Alpes University Hospital, one of France’s leading medical centers. Surrounded by the Chartreuse Mountains, La Tronche offers picturesque landscapes and a tranquil environment, making it a unique blend of natural beauty and historical significance.

  • CT-EU-00112086

    To study the effectiveness of mitotane in preventing cancer recurrence in patients with adrenocortical carcinoma

    The ADIUVO trial is focused on understanding the effectiveness of a treatment called mitotane in patients who have undergone surgery for a rare type of adrenocortical cancer. This cancer has a high chance of coming back after surgery, and previous research suggests that mitotane may help reduce this risk. However, it is important to confirm these results in a study in which patients are randomly assigned to receive mitotane or no additional treatment after surgery. This is particularly important for patients whose cancer is at low or intermediate risk of coming back because doctors need to be sure that the benefits of mitotane outweigh any side effects.

    In this study, the goal is to see if mitotane can help patients live longer without their cancer coming back. Doctors will also assess patients’ overall life expectancy, quality of life and any side effects that may occur as a result of treatment. In addition, they will check whether mitotane levels in the blood influence these results and whether there are differences in results depending on certain characteristics of the cancer.

    Treatment with mitotane will be started at a lower dose and gradually increased depending on your tolerability, with adjustments possible depending on blood levels and side effects. The main goal is to compare how long patients remain cancer-free after surgery, with particular emphasis on their overall well-being and any potential side effects of treatment.

    FranceGermanyItalyNetherlandsUnited Kingdom
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

  • Examining repotrectinib vs crizotinib in advanced lung cancer treatment

    This trial is named TRIDENT-3, it’s for people who have a particular type of lung cancer that has spread beyond the lungs (advanced or metastatic). The lung cancer for this study is called ‘Non-Small Cell Lung Cancer’ (NSCLC) and it’s positive for an important part of the cells called ‘ROS1.’ The trial will compare two medicines: repotrectinib and crizotinib. People participating in the trial have not been treated with a group of drugs called ‘Tyrosine Kinase Inhibitors’ (TKIs) before. The main goal of this study is to see how effective and safe these two drugs are for these patients.

  • Fianlimab and cemiplimab: a new treatment for melanoma patients

    The study is underway to determine the most effective treatments in preventing the recurrence of melanoma, a form of skin cancer, following surgical removal. The medicines being tested are Fianlimab and Cemiplimab together or another medicine called Pembrolizumab. The trial aims to assess whether the Fianlimab and Cemiplimab combination outperforms Pembrolizumab in preventing cancer recurrence and if patients administered Fianlimab and Cemiplimab live longer. Additionally, the study seeks insights into the impact of treatments on patients’ quality of life, the occurrence of minor or major side effects, and how these drugs behave inside the patient’s body.

    BelgiumCzechiaFranceGermanyGreeceItalyPolandRomaniaSpainUnited Kingdom
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    AustriaFinlandFranceGermanyItalyNetherlandsNorwayPolandPortugalSloveniaSpainSwedenUnited Kingdom
  • Study of lacutamab in T-cell lymphoma

    This trial involves a medication called lacutamab, which will be given to patients who have a type of blood cancer known as peripheral T-cell lymphoma, and their disease has either come back after previous treatment or didn’t respond at all. Some patients in the study will receive lacutamab in combination with a common chemotherapy drugs gemcitabine and oxaliplatine, while others will get only gemcitabine and oxaliplatine. A key aim of this study is to find out if lacutamab is both safe and effective. The study is designed not to compare the two treatments directly, but to check our assumptions for deciding the number of people for the trial. The number of participants getting lacutamab is bigger.

  • Testing a Wharton’s jelly extracts for chronic keratitis

    This clinical trial investigates the use of a specialized eye drop made of extract of umbilical cord lining constituted of Wharton’s jelly to treat chronic keratitis, an enduring eye condition that often manifests with symptoms like dryness, redness, and eye pain. Since conventional treatments have been ineffective, this study aims to evaluate the efficacy of this novel approach. During the trial, doctors will meticulously monitor these symptoms using a scoring system to assess their frequency and severity. They will also examine the skin around the eyes and monitor any changes in vision. Furthermore, they will employ a special dye called fluorescein to detect alterations in the eye’s surface and evaluate the patients’ visual acuity.

  • Studying the safety and effectiveness of a new drug for ulcerative colitis

    This study focuses on examining a drug called ABBV-668, administered in oral capsules, to evaluate its safety and effectiveness in the treatment of adults with ulcerative colitis, a gastrointestinal disease characterized by bleeding and inflammation in the large intestine. About 40 participants will take the capsules twice a day for 16 weeks. After this treatment period, doctors will continue to monitor participants for an additional month. The study involves visiting a doctor more often than usual, carefully checking for potential side effects, and asking participants-specific questions. To measure changes in participants’ condition, doctors will use a special scoring system.

  • Testing mavacamten for heart muscle disease

    This study aims to assess a drug called Mavacamten for a heart condition called Non-Obstructive Hypertrophic Cardiomyopathy. Patients will be randomly given either the actual drug or a placebo without anyone knowing which one they’ve received. The study will measure how safe and effective the drug is for patients with symptoms of this heart condition. The success of the drug will be determined by preventing heart-related issues such as heart attacks, strokes, heart failures, irregular heartbeats, and the need for a heart-rhythm controlling device.

    AustriaBelgiumCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsNorwayPolandPortugalSpainUnited Kingdom
  • Study of a new therapy for the treatment of advanced solid cancer cases

    A two-part clinical trial is being conducted for individuals with advanced solid tumors by a research group. A novel drug, [177Lu]-NeoB, is under examination to determine its safety, tolerability, and efficacy against various cancer types such as breast, lung, and prostate. The trial is divided into two phases. In the initial phase, the dosage will be incrementally increased to identify the maximum tolerable amount without inducing severe side effects. Subsequently, in the second phase, this determined dose will be utilized to assess the treatment’s effectiveness. The focus of the trial is on individuals with advanced solid cancers, including breast, lung, prostate, and stomach, as existing therapies may not be suitable or effective for these cases. The investigated drug targets a specific protein on cancer cells to inhibit their growth. To monitor effects and ensure safety, the concentration of the drug in the body will be regularly measured, changes in tumor size observed, and any side effects recorded. This trial has the potential to yield valuable insights into the treatment of advanced cancers, potentially introducing a new therapeutic option.

    AustriaFranceNetherlandsSpainUnited Kingdom
  • Monitoring the long-term safety of Nivolumab for cancer survivors

    This study is designed to understand the long-term effects of a medicine called Nivolumab in patients who have fought against various forms of cancer. In this study, the focus is on closely examining the long-term efficiency and safety of Nivolumab. Participants in the investigation encompass both current and past users of Nivolumab.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainUnited Kingdom
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Research of combination therapy for metastatic melanoma

    This study looks into a new test treatment for serious skin cancer. It’s a big study, happening in multiple places. It will look at two things: one, a drug called HBI-8000 (Tudicdinostat) taken together with another drug called Nivolumab, and two, just Nivolumab on its own. The main goal is to see which approach works better for patients. Patients who can take part are ones who haven’t tried specific cancer treatments before (PD-1 or PD-L1 inhibitors). However, young people or people with quickly worsening brain tumors can’t take part. The patients are picked based on whether a certain substance is present in their cancer cells (PD-L1 expression) and the LDH level that’s found in their blood.

    AustriaBelgiumCzechiaFranceGermanyItalySpainUnited Kingdom
  • Examining the efficacy of Imlifidase in kidney transplant patients

    This study will test the drug imlifidase on patients who require a kidney transplant but have a condition that makes their body reject the new organ. In this study, the goal is to assess the effectiveness of imlifidase in facilitating acceptance of new organs among patients and evaluating the kidney’s functionality one year post-transplant. The patients, who must consent after being made aware of the risks, will be compared to two groups — one group who has recently received a transplant and another historical group from records of transplants. Imlifidase works by removing harmful antibodies quickly, allowing the body to accept the new organ. But after the transplant, these antibodies can come back. Therefore, patients in this study will be closely watched for any signs of their body rejecting the new organ, like through blood tests and organ checks at 6 months and 1 year.

    AustriaBelgiumCzechiaFranceItalyNetherlandsSpainSwedenUnited Kingdom
  • Thrombolysis therapy in treating acute Pulmonary Embolism

    This study aims to evaluate a reduced dose of thrombolytic treatment for patients with intermediate-high-risk acute pulmonary embolism. It compares the new treatment approach with a placebo to assess effectiveness and safety. The study’s focus is on reducing the risk of major and intracranial bleeding associated with full-dose thrombolytic treatment. Participants will receive either the experimental treatment or a placebo, alongside standard anticoagulation therapy. The primary goal is to determine the efficacy and safety of the reduced dosage at day 30, with long-term follow-up assessments planned. This research is crucial for improving treatment options for patients with this serious lung condition.

  • Testing zibotentan/dapagliflozin’s effect on kidney disease and high protein

    This clinical trial seeks to understand how well the combination of two medications, zibotentan and dapagliflozin, work together compared to dapagliflozin alone in patients with chronic kidney disease and high-protein levels in their urine. The researchers are interested in learning if this combination treatment can slow the deterioration of kidney function better than dapagliflozin alone. They will also be looking at whether it can decrease the amount of protein and albumin in the urine, reduce the likelihood of severe kidney problems or death due to kidney disease, and lessen high blood pressure better than dapagliflozin on its own.

    AustriaBulgariaDenmarkFranceGermanyItalyNetherlandsNorwaySlovakiaSpainSwedenUnited Kingdom
  • New hepatocellular carcinoma treatment study: evaluating a combination of atezolizumab, bevacizumab, and tiragolumab

    This clinical trial is focused on patients with untreated, advanced liver cancer, known as hepatocellular carcinoma (HCC). It aims to determine the effectiveness and safety of a new treatment combination. The trial involves two main drugs, atezolizumab and bevacizumab, and tests the addition of a third drug, tiragolumab, for some participants. These medications are given intravenously every three weeks. The trial is designed as a randomized, double-blind study, meaning participants are randomly assigned to different treatment groups without knowing which treatment they receive. The study will measure how long patients live without the disease getting worse (progression-free survival) and overall survival. It will also assess the response rate to the treatment, how long the response lasts, and any side effects. Additionally, the trial evaluates the participants’ quality of life and monitors drug concentrations in the blood. This study is significant for patients with HCC, offering a potential new treatment option that could improve their outcomes and quality of life.

  • Testing new drug on advanced skin cancer patients

    The aim of this study is to evaluate a new treatment called INCB099280 for adults with advanced cutaneous squamous cell carcinoma (cSCC). This is a phase II trial that will evaluate the efficacy and safety of INCB099280 in participants with metastatic or locally advanced cSCC. The study will consist of two parts, differing in the level of treatment doses. Participants will receive treatment twice daily for up to 2 years. The primary goal is to determine the objective response rate (ORR), which measures the percentage of participants who achieved a complete or partial response. Secondary outcome measures include disease control rate, duration of response, time to response, progression-free survival, and overall survival. Eligible participants should have a histopathological diagnosis of cSCC and measurable disease.


See more clinical trials in other cities in France: